Phase 3 Study of Ixazomib in Select Multiple Myeloma Patients Reports Benefits
Takeda Pharmaceutical Co. has announced that Ninlaro (ixazomib),…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreTakeda Pharmaceutical Co. has announced that Ninlaro (ixazomib),…
Researchers in the Sylvester Comprehensive Cancer Center at the…
A subunit of a signaling protein may be a new therapeutic target…
A new class of drugs that activate a protein…
Researchers at Buffalo, New York-based Roswell Park Cancer Institute…
Researchers at The University of Texas MD Anderson…